Auste­do, Teva's bright spot as it ex­e­cutes turn­around, fails two Touret­te's tri­als

It was all go­ing so well. Last week, Te­va in­vestors saw the light at the end of the tun­nel, af­ter Is­rael’s largest drug­mak­er hand­some­ly beat Wall Street sales ex­pec­ta­tions by $100 mil­lion — fol­low­ing years of de­cline, pre­cip­i­tat­ed by falling rev­enue, le­gal costs and mount­ing debt.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER